INmune Bio Inc banner

INmune Bio Inc
NASDAQ:INMB

Watchlist Manager
INmune Bio Inc Logo
INmune Bio Inc
NASDAQ:INMB
Watchlist
Price: 1.39 USD 2.96% Market Closed
Market Cap: $37m

Wall St Price Targets

INMB Price Targets Summary
INmune Bio Inc

Wall Street analysts forecast INMB stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for INMB is 7.14 USD with a low forecast of 4.04 USD and a high forecast of 9.45 USD.

Lowest Forecast
Price Target
4.04 USD
191% Upside
Average Forecast
Price Target
7.14 USD
414% Upside
Highest Forecast
Price Target
9.45 USD
580% Upside
INmune Bio Inc Competitors:
Price Targets
NSIT
Insight Enterprises Inc
27% Upside
AFYA
Afya Ltd
18% Upside
QLYS
Qualys Inc
47% Upside

Revenue
Forecast

N/A
Past Growth
206% / Year
Estimated Growth
Estimates Accuracy
31%
Average Beat
N/A
Past Growth
206% / Year
Estimated Growth
Estimates Accuracy
31%
Average Beat

The compound annual growth rate for Revenue over the next 8 years is 206%.

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-9%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-9%
Average Miss

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-39%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-39%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is INMB's stock price target?
Price Target
7.14 USD

According to Wall Street analysts, the average 1-year price target for INMB is 7.14 USD with a low forecast of 4.04 USD and a high forecast of 9.45 USD.

What is the Revenue forecast for INmune Bio Inc?
Projected CAGR
206%

The compound annual growth rate for Revenue over the next 8 years is 206%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett